Kevin J Culligan is a senior partner in Goodwin Procter's IP Litigation Group, a member of the firm's Patent Litigation Practice and a member of the firm's FinTech Practice. He has focused his practice for more than 35 years on the litigation, trial, arbitration and appeal of intellectual property matters, concentrating primarily on patent, trade secret and unfair competition cases in the fields of pharmaceuticals, medical devices, biotechnology and financial services.
He is serving or recently has served as lead counsel in litigated patent matters for companies that include Bank of America, Barclays, IBM, Insulet Corporation, Merck KGaA, Merrill Lynch and Teva Pharmaceuticals USA.
Mr Culligan also advises pharmaceutical companies about Hatch-Waxman disputes and about matters involving biosimilars, and he counsels financial services institutions about a wide range of intellectual property matters and proceedings, including post-grant review proceedings in the U.S. Patent Offices Patent Trial and Appeal Board.
Mr Culligan has extensive licensing experience that includes the development and execution of licensing and enforcement programmes involving patent portfolios that include only a few patents to portfolios that comprehend hundreds of patents.
He is a member of the American Bar Association, the American Intellectual Property Law Association (AIPLA), the Federal Circuit Bar Association, the New York City Bar Association and the New York Intellectual Property Law Association (NYIPLA).
Mr Culligan was awarded a JD degree by the Cornell Law School, and he earned a BA in biology at Colgate University. He is a member of the Bar of the US Supreme Court, the US Courts of Appeals for the Federal and Ninth Circuits, and the US District Courts for the Southern, Eastern and Western Districts of New York. He has also been admitted pro hac vice in numerous jurisdictions in the US, and has appeared in civil trials and pretrial proceedings in many states across the country.